Erwin S Schultz
Overview
Explore the profile of Erwin S Schultz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
525
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burda B, Schultz E
Laryngorhinootologie
. 2023 Apr;
102(10):735-741.
PMID: 37054747
Background: The cutaneous squamous cell carcinoma (CSCC) is the second most common nonmelanoma skin cancer with an increasing incidence rate. Patients presenting with high-risk lesions associated with locally advanced or...
2.
Birkner M, Schalk J, von den Driesch P, Schultz E
J Clin Med
. 2022 Dec;
11(23).
PMID: 36498674
(1) Background: Pyoderma gangrenosum (PG) is often situated on the lower legs, and the differentiation from conventional leg ulcers (LU) is a challenging task due to the lack of clear...
3.
Zimmer L, Livingstone E, Krackhardt A, Schultz E, Goppner D, Assaf C, et al.
Eur J Cancer
. 2021 Oct;
158:72-84.
PMID: 34655839
Background: Combination of immune checkpoint inhibitors and mitogen-activated protein kinase (MAPK) pathway inhibitors (MAPKi) has been proposed to enhance the durability of anti-tumour responses induced by MAPKi. Here, we present...
4.
Eglmeier J, Debus D, Schultz E
Eur J Dermatol
. 2020 Apr;
30(1):69-71.
PMID: 32250263
No abstract available.
5.
Baur V, Papadopoulos T, Kazakov D, Agaimy A, Hartmann A, Isbary G, et al.
Virchows Arch
. 2018 Jun;
473(2):241-246.
PMID: 29934657
Multiple familial trichoepitheliomas (MFT) is an autosomal dominantly inherited disease characterized by multiple skin appendage tumors. We describe a patient showing a continuous spectrum of follicular differentiated neoplasms including classical...
6.
Heppt M, Eigentler T, Kahler K, Herbst R, Goppner D, Gambichler T, et al.
Cancer Immunol Immunother
. 2016 Jun;
65(8):951-9.
PMID: 27294607
Growing evidence suggests that concurrent loco-regional and systemic treatment modalities may lead to synergistic anti-tumor effects in advanced melanoma. In this retrospective multicenter study, we evaluate the use of electrochemotherapy...
7.
Doesch J, Debus D, Meyer C, Papadopoulos T, Schultz E, Ficker J, et al.
Lung Cancer
. 2016 Apr;
95:35-8.
PMID: 27040849
Introduction: Afatinib is a tyrosine kinase inhibitor (TKI), that has been approved for treating patients with epidermal growth factor receptor (EGFR) mutated advanced non-small-cell lung cancer (NSCLC). Stevens-Johnson syndrome (SJS)...
8.
Ntasou A, Grummich H, Fischer K, Baur V, Bonkowsky V, Birkmann J, et al.
Eur J Dermatol
. 2015 Oct;
26(1):94-5.
PMID: 26462596
No abstract available.
9.
Erfurt C, Muller E, Emmerling S, Klotz C, Hertl M, Schuler G, et al.
Int J Cancer
. 2009 Jan;
124(10):2341-6.
PMID: 19173283
Melanoma-associated chondroitin sulfate proteoglycan (MCSP) (also known as high molecular weight-melanoma-associated antigen) represents an interesting target antigen for cancer immunotherapy which is expressed on human melanomas and other tumors such...
10.
Erfurt C, Sun Z, Haendle I, Schuler-Thurner B, Heirman C, Thielemans K, et al.
J Immunol
. 2007 Jun;
178(12):7703-9.
PMID: 17548607
To avoid immune escape by down-regulation or loss of Ag by the tumor cells, target Ags are needed, which are important for the malignant phenotype and survival of the tumor....